Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

By Brufsky A.   Fontaine-Rothe P.   Berlane K.   Rieker P.   Jiroutek M.   Kaplan I.   Kaufman D.   Kantoff P.  

Urology, Vol. 49, Iss. 6, 1997-06 ,pp. : 913-920

Elsevier

Access to resources Recommend Favorite

Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy

By Kollermann J.   Caprano J.   Budde A.   Weidenfeld H.   Weidenfeld M.   Hopfenmuller W.   Helpap B.  

Urology, Vol. 62, Iss. 3, 2003-09 ,pp. : 476-480

Elsevier

Access to resources Recommend Favorite

Comparison of proliferating cell nuclear antigen immunostaining in lymph node metastases and primary prostate adenocarcinoma after neoadjuvant androgen deprivation therapy

By Minardi Daniele   Galosi Andrea   Giannulis Ioannis   Montironi Rodolfo   Polito Mario   Muzzonigro Giovanni  

Scandinavian Journal of Urology and Nephrology, Vol. 38, Iss. 1, 2004-02 ,pp. : 19-25

Informa Healthcare

Access to resources Recommend Favorite

Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waiting

By Berge Viktor   Thompson Trevor   Blackman Donald  

Scandinavian Journal of Urology and Nephrology, Vol. 41, Iss. 3, 2007-01 ,pp. : 198-203

Informa Healthcare

Access to resources Recommend Favorite

Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer

By Morote J.   M'Hammed Y.I.D.   Martinez E.   Esquena S.   Lorente J.A.   Gelabert A.  

Urology, Vol. 59, Iss. 2, 2002-02 ,pp. : 277-280

Elsevier

Access to resources Recommend Favorite